Effects of pemafibrate on metabolic parameters in patients with diabetes

Effects of pemafibrate on metabolic parameters in patients with diabetes - Effects of pemafibrate on metabolic parameters in patients with diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038160

Enrollment

500

Registered

2019-10-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes and hypertriglyceridemia

Interventions

Pemafibrate (0.1 mg b.i.d.) was administered for 5 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes having hypertriglyceridemia

Exclusion criteria

Exclusion criteria: Patients having hepatic and renal dysfunction (serum levels of AST, ALT, and gamma-GTP >100 U/L and/or serum creatinine level >2.0 mg/dL)

Design outcomes

Primary

Measure	Time frame
Measurement of serum triglyceride level every 1 month for 5 years	—

Secondary

Measure	Time frame
Measurement of serum levels of cholesterol, glucose, insulin, and hepatic function parameters, HbA1c level, and BMI every 1 month for 5 years	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp+81-52-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026